Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.

Han, Jae Joon

Han, Jae Joon.

Afiliação

Han JJ; Department of Hematology and Medical Oncology, College of Medicine, Kyung Hee University, Seoul, Korea.

Blood Res ; 58(S1): S58-S65, 2023 Apr 30.

Article em En | MEDLINE | ID: mdl-37026381

Palavras-chave

Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Treatment-free remission; Tyrosine kinase inhibitor

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133852
https://dx.doi.org/10.5045/br.2023.2023035

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Blood Res Ano de publicação: 2023 Tipo de documento: Article

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133852
https://dx.doi.org/10.5045/br.2023.2023035

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Blood Res Ano de publicação: 2023 Tipo de documento: Article